Sprint Bioscience AB (publ) (SPRINT.ST)
SEK 1.35
(0.15%)
SEK 1.35
(0.15%)
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2023 | 34.6 Million SEK | 274.73% |
| 2022 | 9.23 Million SEK | 6.35% |
| 2021 | 8.68 Million SEK | -64.2% |
| 2020 | 24.25 Million SEK | 194.82% |
| 2019 | 8.22 Million SEK | -62.68% |
| 2018 | 22.04 Million SEK | 198.09% |
| 2017 | 7.39 Million SEK | -64.83% |
| 2016 | 21.02 Million SEK | -18.54% |
| 2015 | 25.81 Million SEK | 434.79% |
| 2014 | 4.82 Million SEK | 17.47% |
| 2013 | 4.1 Million SEK | 28.24% |
| 2012 | 3.2 Million SEK | 329.45% |
| 2011 | 746.08 Thousand SEK | 0.0% |
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2024 Q1 | 27.61 Million SEK | -20.21% |
| 2024 Q3 | 32.54 Million SEK | 9.91% |
| 2024 Q2 | 29.6 Million SEK | 7.24% |
| 2023 Q2 | 18.8 Million SEK | 3.18% |
| 2023 Q4 | 34.6 Million SEK | 11.8% |
| 2023 Q3 | 30.95 Million SEK | 64.58% |
| 2023 FY | 34.6 Million SEK | 274.73% |
| 2023 Q1 | 18.22 Million SEK | 97.38% |
| 2022 Q2 | 9.36 Million SEK | 22.13% |
| 2022 FY | 9.23 Million SEK | 6.35% |
| 2022 Q4 | 9.23 Million SEK | -0.33% |
| 2022 Q3 | 9.26 Million SEK | -1.01% |
| 2022 Q1 | 7.66 Million SEK | -11.74% |
| 2021 Q3 | 9.91 Million SEK | 17.26% |
| 2021 Q1 | 22.21 Million SEK | -8.43% |
| 2021 Q4 | 8.68 Million SEK | -12.38% |
| 2021 FY | 8.68 Million SEK | -64.2% |
| 2021 Q2 | 8.45 Million SEK | -61.95% |
| 2020 Q1 | 19.8 Million SEK | 140.72% |
| 2020 Q2 | 23.65 Million SEK | 19.47% |
| 2020 Q4 | 24.25 Million SEK | 9.47% |
| 2020 Q3 | 22.15 Million SEK | -6.35% |
| 2020 FY | 24.25 Million SEK | 194.82% |
| 2019 Q4 | 8.22 Million SEK | -0.32% |
| 2019 Q1 | 7.98 Million SEK | -63.79% |
| 2019 FY | 8.22 Million SEK | -62.68% |
| 2019 Q2 | 7.85 Million SEK | -1.6% |
| 2019 Q3 | 8.25 Million SEK | 5.05% |
| 2018 Q2 | 9.44 Million SEK | -4.4% |
| 2018 FY | 22.04 Million SEK | 198.09% |
| 2018 Q4 | 22.04 Million SEK | 176.66% |
| 2018 Q3 | 7.96 Million SEK | -15.65% |
| 2018 Q1 | 9.88 Million SEK | 33.63% |
| 2017 Q4 | 7.39 Million SEK | -19.08% |
| 2017 FY | 7.39 Million SEK | -64.83% |
| 2017 Q3 | 9.14 Million SEK | 2.81% |
| 2017 Q2 | 8.89 Million SEK | -29.98% |
| 2017 Q1 | 12.69 Million SEK | -39.62% |
| 2016 Q1 | 22.16 Million SEK | -14.13% |
| 2016 Q4 | 21.02 Million SEK | -26.57% |
| 2016 FY | 21.02 Million SEK | -18.54% |
| 2016 Q3 | 28.63 Million SEK | 282.14% |
| 2016 Q2 | 7.49 Million SEK | -66.19% |
| 2015 Q3 | 26.86 Million SEK | 435.12% |
| 2015 Q4 | 25.81 Million SEK | -3.91% |
| 2015 FY | 25.81 Million SEK | 434.79% |
| 2015 Q2 | 5.02 Million SEK | -5.03% |
| 2015 Q1 | 5.28 Million SEK | 9.51% |
| 2014 Q4 | 4.82 Million SEK | 7.55% |
| 2014 FY | 4.82 Million SEK | 17.47% |
| 2014 Q1 | - SEK | -100.0% |
| 2014 Q2 | 4.64 Million SEK | 0.0% |
| 2014 Q3 | 4.48 Million SEK | -3.34% |
| 2013 Q4 | 4.1 Million SEK | 0.0% |
| 2013 Q1 | - SEK | 0.0% |
| 2013 FY | 4.1 Million SEK | 28.24% |
| 2012 FY | 3.2 Million SEK | 329.45% |
| 2011 FY | 746.08 Thousand SEK | 0.0% |
| Name | Total Liabilities | Total Liabilities Difference |
|---|---|---|
| NextCell Pharma AB | 13.68 Million SEK | -152.779% |
| Biovica International AB (publ) | 34.76 Million SEK | 0.472% |
| Abliva AB (publ) | 16.78 Million SEK | -106.203% |
| Active Biotech AB (publ) | 13.4 Million SEK | -158.231% |
| Aptahem AB (publ) | 8.99 Million SEK | -284.571% |
| Alligator Bioscience AB (publ) | 106.59 Million SEK | 67.538% |
| BioInvent International AB (publ) | 90.45 Million SEK | 61.745% |
| BioArctic AB (publ) | 139.5 Million SEK | 75.196% |
| Bio-Works Technologies AB (publ) | 16.11 Million SEK | -114.699% |
| Calliditas Therapeutics AB (publ) | 1.56 Billion SEK | 97.79% |
| Cantargia AB (publ) | 54.97 Million SEK | 37.051% |
| Scandinavian ChemoTech AB (publ) | 3.83 Million SEK | -801.589% |
| CombiGene AB (publ) | 4.15 Million SEK | -732.604% |
| Egetis Therapeutics AB (publ) | 214.6 Million SEK | 83.876% |
| Fluicell AB (publ) | 8.91 Million SEK | -288.144% |
| Genovis AB (publ.) | 98.04 Million SEK | 64.708% |
| Hansa Biopharma AB (publ) | 1.18 Billion SEK | 97.082% |
| Mendus AB (publ) | 51.22 Million SEK | 32.449% |
| Karolinska Development AB (publ) | 11.56 Million SEK | -199.101% |
| LIDDS AB (publ) | 3.75 Million SEK | -821.273% |
| QuiaPEG Pharmaceuticals Holding AB (publ) | 26.7 Million SEK | -29.56% |
| Saniona AB (publ) | 86.08 Million SEK | 59.803% |
| Spago Nanomedical AB (publ) | 11.66 Million SEK | -196.563% |
| Xintela AB (publ) | 14.01 Million SEK | -146.9% |
| Amniotics AB (publ) | 10.54 Million SEK | -228.084% |
| Corline Biomedical AB | 6.78 Million SEK | -409.692% |
| Elicera Therapeutics AB (publ) | 13.77 Million SEK | -151.264% |
| Infant Bacterial Therapeutics AB (publ) | 46.18 Million SEK | 25.069% |
| IRLAB Therapeutics AB (publ) | 61.35 Million SEK | 43.604% |
| Intervacc AB (publ) | 21.68 Million SEK | -59.608% |
| Kancera AB (publ) | 17.97 Million SEK | -92.474% |
| Lipum AB (publ) | 7.53 Million SEK | -359.047% |
| Lipigon Pharmaceuticals AB (publ) | 5.15 Million SEK | -570.861% |
| Nanologica AB (publ) | 79.32 Million SEK | 56.379% |
| Vicore Pharma Holding AB (publ) | 40.85 Million SEK | 15.311% |
| Xbrane Biopharma AB (publ) | 482.17 Million SEK | 92.824% |
| AcouSort AB (publ) | 10.37 Million SEK | -233.426% |
| Diamyd Medical AB (publ) | 71.11 Million SEK | 51.344% |
| ExpreS2ion Biotech Holding AB (publ) | 13.32 Million SEK | -159.626% |
| Magle Chemoswed Holding AB (publ) | 123.97 Million SEK | 72.09% |
| Modus Therapeutics Holding AB (publ) | 2.35 Million SEK | -1366.85% |
| Xspray Pharma AB (publ) | 71.85 Million SEK | 51.84% |
| Simris Alg AB (publ) | 148.93 Million SEK | 76.767% |
| Ziccum AB (publ) | 6.38 Million SEK | -441.688% |
| SynAct Pharma AB | 51.83 Million SEK | 33.243% |
| OncoZenge AB (publ) | 1.69 Million SEK | -1936.669% |
| Camurus AB (publ) | 414.81 Million SEK | 91.658% |
| 2cureX AB (publ) | 2.93 Million SEK | -1078.978% |
| Asarina Pharma AB (publ) | 4.42 Million SEK | -681.812% |
| Isofol Medical AB (publ) | 19.16 Million SEK | -80.563% |
| Stayble Therapeutics AB (publ) | 5.19 Million SEK | -566.09% |
| I-Tech AB | 16.2 Million SEK | -113.533% |
| Cyxone AB (publ) | 4.69 Million SEK | -637.175% |
| Biosergen AB | 5.08 Million SEK | -580.492% |
| Annexin Pharmaceuticals AB (publ) | 7.94 Million SEK | -335.313% |
| Alzinova AB (publ) | 9.33 Million SEK | -270.839% |
| Oncopeptides AB (publ) | 181.59 Million SEK | 80.945% |
| Guard Therapeutics International AB (publ) | 18.49 Million SEK | -87.104% |
| Pila Pharma AB (publ) | 1.79 Million SEK | -1828.818% |
| Ascelia Pharma AB (publ) | 12.74 Million SEK | -171.524% |
| Diagonal Bio AB (publ) | 7.26 Million SEK | -376.625% |